---
schema_version: "secwatch.filing_event.v1"
accession: "0001528287-22-000017"
form_type: "8-K"
ticker: "NPCE"
cik: "0001528287"
company_name: "NeuroPace Inc"
filed_at: "2022-08-11T23:59:59+00:00"
generated_at: "2026-06-24T00:48:17.204747+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# NeuroPace Q2 revenue $10.2M (-19% YoY); net loss $12.7M; signs exclusive DIXI Medical SEEG distribution deal

## Summary
- Q2 total revenue $10.2M vs $12.6M YoY; initial implant revenue $8.0M, replacement $2.2M.
- Net loss $12.7M vs $8.5M YoY; operating expenses $18.4M up from $14.0M.
- FY 2022 guidance: total revenue $43-45M, initial implant $34-36M; DIXI Medical revenue ~$1.5M in Q4.
- Signed exclusive 3-year U.S. distribution deal for DIXI Medical SEEG electrodes; total payments of $4.5M.
- Cash and equivalents $92.4M, down from $103.2M at March 31; long-term borrowings $51.0M.

## SEC filing metadata
- accession: 0001528287-22-000017
- form_type: 8-K
- ticker: NPCE
- cik: 0001528287
- company_name: NeuroPace Inc
- filed_at: 2022-08-11T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1528287/000152828722000017/0001528287-22-000017-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1528287/000152828722000017/npce-20220811.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001528287-22-000017
- JSON: https://secwatch.observer/filing/0001528287-22-000017.json
- Plain text: https://secwatch.observer/filing/0001528287-22-000017.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.